
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
TransCelerate BioPharma has launched three new initiatives. The Common Clinical Serious Adverse Events (SAE) Fields Initiative, The Modernization of Data Analytics for Clinical Development Initiative aims, and has expanded its Interpretation of Guidances and Regulations Initiative.
For more on the new initiatives, click






